Cargando…

Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy

Background: Programmed cell death-ligand 1 (PD-L1) is present in a subgroup of cancer patients who may be favorable targets for immune checkpoint inhibitor therapies. However, the significance of the PD-L1 expression in esophageal squamous cell carcinoma (ESCC) patients receiving neoadjuvant chemora...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Wan-Ting, Lu, Hung-I, Wang, Yu-Ming, Chen, Yen-Hao, Lo, Chien-Ming, Lin, Wei-Che, Lan, Ya-Chun, Tseng, Ling-Huei, Li, Shau-Hsuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912507/
https://www.ncbi.nlm.nih.gov/pubmed/31684197
http://dx.doi.org/10.3390/jcm8111864
_version_ 1783479472239935488
author Huang, Wan-Ting
Lu, Hung-I
Wang, Yu-Ming
Chen, Yen-Hao
Lo, Chien-Ming
Lin, Wei-Che
Lan, Ya-Chun
Tseng, Ling-Huei
Li, Shau-Hsuan
author_facet Huang, Wan-Ting
Lu, Hung-I
Wang, Yu-Ming
Chen, Yen-Hao
Lo, Chien-Ming
Lin, Wei-Che
Lan, Ya-Chun
Tseng, Ling-Huei
Li, Shau-Hsuan
author_sort Huang, Wan-Ting
collection PubMed
description Background: Programmed cell death-ligand 1 (PD-L1) is present in a subgroup of cancer patients who may be favorable targets for immune checkpoint inhibitor therapies. However, the significance of the PD-L1 expression in esophageal squamous cell carcinoma (ESCC) patients receiving neoadjuvant chemoradiotherapy remains unclear. Methods: By means of PD-L1 immunohistochemistry 22C3 pharmDx assay, we evaluate the PD-L1 expression and its association with clinical outcome in 107 ESCC patients receiving neoadjuvant chemoradiotherapy. Results: Patients with positive PD-L1 expression have significantly lower pathological complete response rates (13% versus 32%; p = 0.036) than those with negative PD-L1 expression. Univariate survival analysis found that positive PD-L1 expression were correlated with poor overall survival (p = 0.004) and inferior disease-free survival (p < 0.001). In a multivariate analysis, positive PD-L1 expression was independently associated with the absence of a pathologically complete response (p = 0.044, hazard ratio: 3.542), worse overall survival (p = 0.006, hazard ratio: 2.017), and inferior disease-free survival (p < 0.001, hazard ratio: 2.516). Conclusions: For patients with ESCC receiving neoadjuvant chemoradiotherapy, positive PD-L1 expression independently predicts the poor chemoradiotherapy response and worse treatment outcome. Thus, our data suggests that PD-L1 may be an influential biomarker for prognostic classification and for immune checkpoint inhibitor therapies in ESCC patients receiving neoadjuvant chemoradiotherapy.
format Online
Article
Text
id pubmed-6912507
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69125072020-01-02 Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy Huang, Wan-Ting Lu, Hung-I Wang, Yu-Ming Chen, Yen-Hao Lo, Chien-Ming Lin, Wei-Che Lan, Ya-Chun Tseng, Ling-Huei Li, Shau-Hsuan J Clin Med Article Background: Programmed cell death-ligand 1 (PD-L1) is present in a subgroup of cancer patients who may be favorable targets for immune checkpoint inhibitor therapies. However, the significance of the PD-L1 expression in esophageal squamous cell carcinoma (ESCC) patients receiving neoadjuvant chemoradiotherapy remains unclear. Methods: By means of PD-L1 immunohistochemistry 22C3 pharmDx assay, we evaluate the PD-L1 expression and its association with clinical outcome in 107 ESCC patients receiving neoadjuvant chemoradiotherapy. Results: Patients with positive PD-L1 expression have significantly lower pathological complete response rates (13% versus 32%; p = 0.036) than those with negative PD-L1 expression. Univariate survival analysis found that positive PD-L1 expression were correlated with poor overall survival (p = 0.004) and inferior disease-free survival (p < 0.001). In a multivariate analysis, positive PD-L1 expression was independently associated with the absence of a pathologically complete response (p = 0.044, hazard ratio: 3.542), worse overall survival (p = 0.006, hazard ratio: 2.017), and inferior disease-free survival (p < 0.001, hazard ratio: 2.516). Conclusions: For patients with ESCC receiving neoadjuvant chemoradiotherapy, positive PD-L1 expression independently predicts the poor chemoradiotherapy response and worse treatment outcome. Thus, our data suggests that PD-L1 may be an influential biomarker for prognostic classification and for immune checkpoint inhibitor therapies in ESCC patients receiving neoadjuvant chemoradiotherapy. MDPI 2019-11-03 /pmc/articles/PMC6912507/ /pubmed/31684197 http://dx.doi.org/10.3390/jcm8111864 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Huang, Wan-Ting
Lu, Hung-I
Wang, Yu-Ming
Chen, Yen-Hao
Lo, Chien-Ming
Lin, Wei-Che
Lan, Ya-Chun
Tseng, Ling-Huei
Li, Shau-Hsuan
Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy
title Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy
title_full Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy
title_fullStr Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy
title_full_unstemmed Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy
title_short Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy
title_sort positive programmed cell death-ligand 1 expression predicts poor treatment outcomes in esophageal squamous cell carcinoma patients receiving neoadjuvant chemoradiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912507/
https://www.ncbi.nlm.nih.gov/pubmed/31684197
http://dx.doi.org/10.3390/jcm8111864
work_keys_str_mv AT huangwanting positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy
AT luhungi positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy
AT wangyuming positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy
AT chenyenhao positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy
AT lochienming positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy
AT linweiche positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy
AT lanyachun positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy
AT tsenglinghuei positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy
AT lishauhsuan positiveprogrammedcelldeathligand1expressionpredictspoortreatmentoutcomesinesophagealsquamouscellcarcinomapatientsreceivingneoadjuvantchemoradiotherapy